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Both gemcitabine and weekly 24-h infusion of high-dose 5-fluorouracil/leucovorin (HDFL) have shown promising antitumour activity
for patients with locally advanced or metastatic carcinoma of the biliary tract (CBT). From April 1999 through December 2002, 30
patients with inoperable CBT were treated with gemcitabine 800mgm
 2, intravenous infusion for 30min, followed by 5-FU,
2000mgm
 2 and leucovorin, 300mgm
 2, intravenous infusion for 24h, on day 1, 8 and 15, every 4 weeks. A total of 166 cycles
were given (median of four cycles per patient, range 1–24 cycles). Response was evaluable in 28 patients and toxicity in 29 patients.
Partial response was obtained in six patients, stable disease in 13, while progressive disease occurred in nine. The objective response
rate was 21.4% (95% CI: 5.2–37.6%). The most common grade 3 or 4 toxicity was infection (nine patients). Other types of grade 3
or 4 toxicity included leucopenia (four patients), thrombocytopenia (three patients), anaemia (three patients), nausea/vomiting (two
patients) and elevation of liver transaminases (three patients). As of 30 September 2003, the median progression-free survival was 3.7
months (95% CI: 2.8–4.6 months) and the median overall survival was 4.7 months (95% CI: 0.8–8.6 months). Our data suggest that
weekly gemcitabine plus HDFL is modestly active with acceptable treatment-related toxicity for patients with advanced CBT.
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Carcinoma of the biliary tract (CBT) is uncommon, accounting for
about 5% of primary cancers of the hepatobiliary system.
Clinically, CBT is characterized by a very poor prognosis owing
to late diagnosis, anatomic limitation for radical resection, early
dissemination and lack of effective treatment other than surgery.
Most patients with advanced disease die of hepatic failure or
biliary sepsis within 6–12 months of diagnosis (de Groen et al,
1999).
The results of systemic chemotherapy for CBT have been
disappointing. 5-Fluorouracil (5-FU) remains the most effective
agent with a tumour response rate of around 10% (Falkson et al,
1984; Oberfield and Rossi, 1988). The addition of other agents,
such as mitomycin C, doxorubicin or cisplatin, has not shown
consistent benefit in terms of either tumour response or survival
(Harvey et al, 1984; Taal et al, 1993; Okada et al, 1994). Conduct of
large-scale clinical trials of chemotherapy for CBT is difficult
because of its low incidence and the poor general condition of
patients with CBT. Nevertheless, it is needed to develop new
chemotheraputic regimens with better anticancer activity and
better toxicity profile for patients with CBT.
Gemcitabine (2,2-difluorodeoxycytidine) is a novel antimetabo-
lite active against lung, pancreas, breast, bladder and ovarian
cancers (Kaye, 1994). Gemcitabine is currently the only drug
approved by the FDA for the treatment of advanced pancreatic
cancer (Burris et al, 1997). Since the biliary tract and pancreas
share a common embryonal origin, the possibility that gemcitabine
may also be active against CBT has recently been investigated. The
results of these studies, most of them were small-series phase II
trials, have generally supported a beneficial role of gemcitabine in
the treatment of CBT (Raderer et al, 1999; Gebbia et al, 2001;
Scheithauer 2002).
Weekly 24-h infusion of high-dose 5-FU (2600mgm
 2) and
leucovorin (300mgm
 2), the HDFL regimen, has been demon-
strated to be effective against colorectal and gastric cancers
(Ardalan et al, 1991; Hsu et al, 1997; Yeh et al, 1997). Although the
dose of 5-FU in HDFL is much higher than that of the conventional
bolus 5-FU regimens such as the Mayo protocol, the resulting bone
marrow toxicities are surprisingly low. For example, with HDFL
alone, the likelihood of developing grade 3 or 4 haematological
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ltoxicities has been reported as below 3%. We have recently
clarified the mechanisms responsible for the low marrow toxicities
of the HDFL regimen (Yeh et al, 2000a). Further, in an in vitro
experiment mimicking the pharmacokinetics of HDFL, prolonged
exposure of gastric cancer cells to 2.5–5mM of 5-FU resulted in a
more durable suppression of thymidylate synthase and enhanced
cytotoxicity (Yeh et al, 2000b). The possibly better therapeutic
index of HDFL in gastrointestinal tract malignancies, as compared
with the bolus 5-FU regimens (O’Dwyer et al, 2001; Koehne et al,
2003, Saltz, 2003), has made it an ideal component for combination
chemotherapy of CBT.
This study sought to clarify the effectiveness and toxicity of the
combination of gemcitabine and HDFL in the treatment of CBT.
PATIENTS AND METHODS
Patients
Eligibility criteria for this study included (1) histologically or
cytologically proven intrahepatic or extrahepatic cholangiocarci-
noma, papilla vater carcinoma or gallbladder carcinoma that were
inoperable because of either locally advanced disease (AJCC T4
classification, tumours invading main portal vein or hepatic artery
or invading multiple extrahepatic organs or structures), or
evidence of distant metastasis (AJCC M1 classification ) (Fleming,
1997); (2) age between 18 and 70 years; (3) bidimensionally
measurable disease; (4) Karnofsky performance status X60%; (5)
white blood cell (WBC) count X4000ml
 1, absolute neutrophil
count X1500ml
 1, platelet count X150000ml
 1, serum alanine
and aspartate aminotransferases levels p5 times upper normal
limit, total bilirubin p5mgdl
 1, serum creatinine p1.5mgdl
 1
and serum triglyceride level X70mgdl
 1. A low limit for serum
triglyceride was set in order to avoid HDFL-related hyperammo-
nemic encephalopathy (Yeh and Cheng, 1997). No prior cytotoxic
chemotherapy was allowed, except for low-dose chemotherapy
used as a radiosensitiser. Prior radiotherapy was acceptable
if it had been completed at least 6 weeks before enrollment in
this study and did not involve the index tumour lesion for
evaluation of tumour response. This study was approved by
the Institutional Review Board of National Taiwan University
Hospital. All patients had signed informed consent prior to
enrollment in the study.
Treatment plan
The protocol treatment consisted of gemcitabine, 800mgm
 2i.v.
for 30min, followed by 5-FU, 2000mgm
 2, plus leucovorin,
300mgm
 2, i.v. for 24h, on days 1, 8 and 15. The treatment cycle
was repeated every 4 weeks. The drugs were delivered via a Port-A
catheter on an outpatient basis.
The doses of both gemcitabine and HDFL on days 8 and 15
within a cycle were reduced by 25% of the planned doses if the
WBC count was less than 2500ml
 1 or platelet count was less than
75000ml
 1 on the scheduled day of administration, or if grade 3
nonhaematological toxicity (except for nausea/vomiting) occurred
after the previous dose. Doses of gemcitabine and HDFL on days 8
and 15 were omitted if the WBC count was less than 1000ml
 1 or
platelet count was less than 50000ml
 1, or if grade 4 nonhaema-
tological toxicity (except for nausea/vomiting) occurred. A new
cycle was started if the WBC count was more than 4000ml
 1,
platelet count was more than 100000ml
 1, and nonhaematological
toxicity (except for nausea/vomiting) was less than grade 3. If the
patient did not recover from toxicity resulting from treatment on
the scheduled day 1, the protocol treatment was postponed until
the resolution of toxicity. If the new cycle had to be postponed for
more than 8 weeks, the patient was removed from the protocol
treatment.
Evaluation of tumour response and toxicity
During the protocol treatment, the patients were evaluated every
week with a routine history taking and physical examination.
Hemogram was checked before each administration of protocol
treatment, and serum biochemistry, electrolytes and prothrombin
time were checked before each cycle. The tumour response was
evaluated by imaging studies at least once every 2 cycles. Patients
who received two or more cycles of the protocol treatment were
considered evaluable for tumour response and those who had
completed one or more cycles were considered evaluable for
toxicity.
Tumour response and toxicity were evaluated according to
World Health Organization criteria (Miller et al, 1981). Patients
with progressive disease (PD) were removed from the protocol
treatment. Patients with complete response (CR) received three
additional cycles after the documentation of CR, and then the
protocol treatment was stopped. Patients with partial response
(PR) continued with the protocol treatment until PD or prohibitive
toxicity developed. Patients with stable disease (SD) after four
cycles of the protocol treatment could either continue with the
protocol treatment until PD or prohibitive toxicity developed, or
stop the protocol treatment at the discretion of the attending
physician.
Statistical analysis
Simon’s optimal two-stage phase II trial design was used to
estimate the number of patients needed in this study (Simon,
2001). The results of this estimation indicated that for a lower
activity level of 5% and a higher activity level of 20%, at least one
responders should be seen in the first 10 patients and a total of 29
patients should be accrued to obtain a false-positive rate of 5% and
a false-negative rate of 10%.
The median follow-up time was calculated by constructing a
Kaplan–Meier survival curve for all participating patients and
reversing the ‘event’ and ‘censor’. The 50% point of this curve then
indicated the median follow-up time (Shuster, 1991). Progression-
free survival was defined as the duration from the date of starting
the treatment to the date of documented disease progression, death
by any cause, or last follow-up. Overall survival was defined as the
duration from the date of starting protocol treatment to the date of
patient death or last follow-up. Both the progression-free and the
overall survival were calculated using the Kaplan–Meier method.
The difference in clinical parameters between responders and
nonresponders to protocol treatment was evaluated by w
2 test or
Wilcoxon rank-sum test.
RESULTS
Patients
From April 1999 through November 2002, 30 patients (16 men, 14
women) were enrolled in this study. The median age was 55.2 years
(range 30.8–72.5 years). The clinical characteristics of these
patients are summarized in Table 1. A total of 15 patients had
recurrent disease after prior curative surgery and 15 patients had
unresectable advanced or metastatic disease. A total of 14 patients
had obstructive jaundice that required biliary drainage (13
percutaneous transhepatic biliary drainage; one internal biliary
stent) before enrollment. At the end of periodic monitoring for this
study on 30 September 2003, the median duration of follow-up was
43.6 months.
Treatment
A total of 166 cycles of the protocol treatment were administered.
The median number of cycles given per patient was 4 (range: 1–
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The causes of modification included infection (four patients),
thrombocytopenia (three patients), leucopenia (two patients),
anaemia (one patient) and hepatic toxicity (one patient).
Response
In total, 28 patients were evaluable for response. No patient
achieved CR, while six patients (four women; two men) achieved
PR. The overall response rate was 21.4% (95% CI: 5.2–37.6%) for
the evaluable patients and 20% (95% CI: 4.8–35.2%) for the intent-
to-treat. There was no significant difference in the clinicopatho-
logical features between the responders and nonresponders in
terms of age, sex, performance status, primary site of tumour
(cholangiocarcinoma, gallbladder carcinoma, common bile duct
carcinoma or ampula vater carcinoma), disease stage (locally
advanced or metastatic) and pre-existing biliary tract obstruction.
All responders had improvement in tumour-related symptoms and
performance status. In all, 13 patients had SD and nine patients
had PD. The performance status of all patients with SD remained
stationary during the protocol treatment, with a median of four
treatment cycles.
The median progression-free and overall survival for all of the
30 patients were 3.7 months (95% CI: 2.8–4.6 months) and 4.7
months (95% CI: 0.8–8.6 months), respectively (Figure 1). At the
end of periodic monitoring for this study, the overall survival for
the six responders was 4.7, 10.2, 9.9, 23.4, 43.6þ and 10.8þ
months, respectively.
Toxicity
A total of 29 patients were evaluable for toxicity. As summarized in
Table 2, the most common grade 3 or 4 toxicity was infection,
which occurred in nine patients. Eight of the nine patients had
biliary tract infection and six of them had pre-existing biliary tract
obstruction that required biliary drainage during the protocol
treatment. The biliary tract infection resulted in withdrawal from
the protocol treatment in five patients.
DISCUSSION
In this study, we found that weekly gemcitabine plus HDFL was
only moderately active for patients with advanced CBT. This
regimen was in general well tolerated, but patients with underlying
biliary tract obstruction were at increased risk of developing
biliary tract infection.
The present study is one of the largest reported series of
combination chemotherapy with gemcitabine for advanced CBT.
The objective response rates of reported studies have varied widely
Table 1 Clinicopathological features of the patients
Parameters Number of patients (%)
Karnofsky performance status (%)
100 2 (6.7)
90 13 (43.3)
80 10 (33.3)
70 3 (10.0)
60 2 (6.7)
Primary site of tumour
Intrahepatic cholangiocarcinoma 16 (53.3)
Carcinoma of common bile duct 2 (6.7)
Carcinoma of ampulla vater 7 (23.3)
Carcinoma of gallbladder 5 (16.7)
Prior therapies
Curative surgery 15 (50.0)
Palliative surgery 3 (10)
Radiotherapy 2 (6.7)
Chemoradiotherapy 1 (3.3)
TACE
a 1 (3.3)
Sites of metastases
Liver 25 (83.3)
Lung 5 (16.7)
Bone 1 (3.3)
Lymph nodes 8 (26.7)
Others
b 5 (16.7)
Biliary tract obstruction
Yes 14 (46.6)
No 16 (53.4)
aTransarterial chemoembolisation.
bIncluding adrenal gland, pleura, peritoneum,
abdominal wall and duodenum.
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Figure 1 The overall and progression-free survival curves of the patients.
Table 2 Toxicity profiles of gemcitabine–HDFL
WHO toxicity grades
12 3 4
Hematological
Leucopenia 9 (31.0) 3 (10.3) 2 (6.9) 2 (6.9)
Anaemia 8 (27.6) 14 (48.3) 2 (6.9) 1 (3.4)
Thrombocytopenia 1 (3.4) 3 (10.3) 0 (0.0) 3 (10.3)
Non-haematological
Infection 0 (0.0) 5 (17.2) 5 (17.2) 4 (13.8)
Fever 3 (10.3) 16 (55.2) 1 (3.4) 0 (0.0)
Nausea/vomiting 12 (30) 3 (10.3) 2 (6.9) 0 (0.0)
Diarrhoea 8 (27.6) 5 (17.2) 0 (0.0) 1 (3.4)
Constipation 0 (0.0) 4 (13.8) 0 (0.0) 0 (0.0)
Alopecia 10 (33.3) 4 (13.3) — —
Hand–foot syndrome 1 (3.4) 0 (0.0) 0 (0.0) 0 (0.0)
Hepatic toxicity 2 (6.7) 4 (13.3) 0 (0.0) 3 (10.3)
Renal toxicity 3 (10.3) 1 (3.4) 1 (3.4) 1 (3.4)
Neurotoxicity 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Values are number of patients (percentage).
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land are difficult to compare because of possible bias in patient
selection. In these previous studies, the dosage of gemcitabine
ranged from 800 to 1200mgm
 2week
 1, but the optimal dosing
and schedule of gemcitabine remained undetermined. Although a
dose–response relationship for gemcitabine has been suggested by
previous studies, the potential benefit of higher doses of
gemcitabine must be balanced with the increased risk of toxicity.
Although some investigators suggested that a fixed dose-rate
infusion of gemcitabine may improve its antitumour activity, the
clinical benefit of this approach remains to be determined.
(Fossella et al, 1997; Touroutoglou et al, 1998; Tempero et al,
2003).
It has been suggested that addition of 5-FU/leucovorin
will further improve the therapeutic efficacy of gemcitabine
in CBT. Gebbia et al (2001) reported two consecutive studies
of gemcitabine with or without 5-FU/leucovorin for patients
with biliary tract cancer. They found that gemcitabine,
1000mgm
 2i.v. on days 1, 8 and 15 every 5 weeks, had an
objective response of 22% (95% CI: 6–48%) in 18 evaluable
patients; while addition of 5-FU, 400mgm
 2i.v. bolus, followed by
600mgm
 2i.v. for 22h, and leucovorin, 100mgm
 2i.v. for 2h, to
gemcitabine, 1000mgm
 2, on days 1 and 8 every 3 weeks,
produced an objective response of 36% (95% CI: 17–59%) in 22
evaluable patients. Addition of 5-FU/leucovorin did not appear to
increase the severity of toxicity. The regimen of 5-FU/leucovorin
used by Gebbia et al, first described by de Gramont et al, has been
commonly applied in the treatment of metastatic colorectal cancer;
and it has been suggested that higher total doses of 5-FU, similar to
those used in our study, may further enhance the antitumour
activity of 5-FU/leucovorin (de Gramont et al, 1998; Koehne et al,
1998). Further studies are warranted to explore the optimal dosing
and combination schedule for gemcitabine and 5-FU/leucovorin
infusion.
Preliminary reports of other gemcitabine-containing che-
motherapy regimens have shown promising activity for patients
with advanced CBT. Objective response rate of more than 30% for
patients with advanced CBT was reported by using the combina-
tions of gemcitabine with cisplatin or oxaliplatin (Andre et al,
2001; Carraro et al, 2001; Doval et al, 2001). It is difficult, however,
to compare directly the response rate in different trials because of
the relatively small sample size and the heterogeneous patient
populations of their series. In these and also the report by Gebbia
et al, gallbladder cancer comprised the majority of the patient
population. In contrast, intrahepatic cholangiocarcinoma was the
most common diagnosis in our study. The relationship between
chemosensitivity and cellular origin of CBT, as well as the
differential activity of gemcitabine, cisplatin and oxaliplatin on
advanced CBT, remains to be clarified.
The relatively high incidence of biliary tract infection in our
patients is an important concern. Concurrent grade 3 or 4
myelotoxicity was rare in our study, and pre-existing obstructive
jaundice and the relatively poor general condition were the most
important risk factors for developing biliary tract infection. The
relatively poor general condition of our patients was also suggested
by the short median overall survival (4.7 months), which
compared unfavourably with those reported in other series (5–
12 months) (Hejna et al, 1998; Gebbia et al, 2001). Therefore,
careful selection of patients for chemotherapy is essential to
decrease the incidence of this complication. On the other hand,
cumulative toxicity resulting from the gemcitabine plus HDFL
regimen was infrequent. Two of our patients had received more
than 10 cycles of protocol treatment and remained in PR without
evidence of any cumulative toxicities at the end of periodic
monitoring for this study.
We conclude that gemcitabine plus HDFL is well tolerated and
modestly active in selected patients with advanced CBT. Improve-
ment in the quality of life can be reasonably expected in patients
who respond to chemotherapy.
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